Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
NCT00959192
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Alzheimer's Disease
Interventions
BIOLOGICAL:
ACC-001
OTHER:
QS-21
OTHER:
QS-21
Sponsor
Pfizer
Collaborators
[object Object]